Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pipeline Review: Large Potential Overactive Bladder Population Beckons

Executive Summary

Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.

Advertisement

Related Content

Deal Watch: Emergent Strikes Again, Acquiring Adapt And Its Opioid Overdose Drug For $635m
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC
Allergan gains US FDA nod for Botox in overactive bladder

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel